

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease

<https://marketpublishers.com/r/F3456F708B0EN.html>

Date: April 2018

Pages: 77

Price: US\$ 6,995.00 (Single User License)

ID: F3456F708B0EN

Abstracts

Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease

SUMMARY

Type 2 diabetes mellitus (T2DM) is a major metabolic disease and one of the leading causes of death worldwide. The prevalence is on the rise, alongside increases in obesity due to lifestyle changes in the 21st century.

Type 2 diabetes is characterized by insulin resistance leading to dysregulation of glucose control and chronic hyperglycemia. This leads to several co-morbidities and complications, some of which are associated with damage to blood vessels as a result of elevated blood glucose levels.

The disease is progressive: patients' standard of living deteriorate over time and the symptoms worsen, meaning more complex treatment regimens are required over time.

The complexity of the treatment means there is a high diversity of marketed products. In recent years new drug types have been great commercial successes and reached blockbuster status.

This alongside the financial cost of type 2 diabetes to healthcare providers has led to significant investment in R&D on therapeutics in this area.

SCOPE

Requirement for new types of therapeutics to add to already complex treatment algorithms for severe T2DM

What are the most important etiological risk factors and pathophysiological processes implicated in T2DM?

What is the current treatment algorithm?

How effective are current therapies for these indications, and how does this impact prognosis? What are the side effects associated with these treatments?

The T2DM pipeline is dominated by G-protein-coupled receptors (GPCRs) and protein kinases

Which molecule types and molecular targets are most prominent in the T2DM pipeline?

Which first-in-class targets are most promising?

How does the level of first-in-class innovation change within different target classes?

How does first-in-class target diversity differ by stage of development and molecular target class?

The deals landscape is active and dominated by products that target GPCRS and protein kinases

Which molecular types/molecular target groups attract the highest deal values?

How has deal activity fluctuated over the past decade?

Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

REASONS TO BUY

Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, and diagnosis and treatment options.

Identify leading products and key unmet needs within the market.

Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

Assess the therapeutic potential of first-in-class targets. Using proprietary matrix assessments, first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Individual matrix assessments are provided for targets identified in the pipeline for T2DM. Promising early-stage first-in-class targets are reviewed in greater detail.

Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Contents

1 TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2 EXECUTIVE SUMMARY

- 2.1 Competitive Market Landscape Driven by Rising Prevalence
- 2.2 Large and Diverse Pipeline Dominated by Products Acting on G Protein Coupled Receptors (GPCR) and Protein Kinases
- 2.3 Strong Opportunities for Investment in First-in-Class Products

3 THE CASE FOR INNOVATION

- 3.1 Growing Opportunities for Biologic Products
- 3.2 Diversification of Molecular Targets
- 3.3 Innovative First-in-Class Product Developments Remain Attractive
- 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Innovation
- 3.5 Sustained Innovation in Type 2 Diabetes Mellitus

4 CLINICAL AND COMMERCIAL LANDSCAPE

- 4.1 Overview of Type 2 Diabetes Mellitus
- 4.2 Disease Classification
 - 4.2.1 Type 1 Diabetes Mellitus
 - 4.2.2 Type 2 Diabetes Mellitus
 - 4.2.3 Type 3 Diabetes Mellitus
 - 4.2.4 LADA
 - 4.2.5 MODY
 - 4.2.6 Gestational
 - 4.2.7 Pancreatic diabetes
 - 4.2.8 Prediabetes
- 4.3 Symptoms
- 4.4 Diagnosis
- 4.5 Etiology
- 4.6 Pathophysiology
- 4.7 Comorbidities and Complications

- 4.8 Epidemiology
- 4.9 Treatment
 - 4.9.1 Non-Insulin T2DM Therapies
 - 4.9.2 Insulin-Based T2DM Therapies
- 4.10 Overview of Marketed Products
- 4.11 Unmet Need and Commercial Opportunities in T2DM

5 ASSESSMENT OF PIPELINE PRODUCT INNOVATION

- 5.1 Overview
- 5.2 Pipeline by Stage of Development and Molecule Type
- 5.3 Pipeline by Molecular Target
- 5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class
- 5.5 Comparative Distribution of First-in-Class and Non-First-in-Class Pipeline Programs by Molecular Target Class
- 5.6 Ratio of First-in-Class Programs to First-in-Class Molecular Targets within the Pipeline
- 5.7 List of All First-in-Class Pipeline Programs

6 SIGNALING NETWORK, DISEASE CAUSATION AND INNOVATION ALIGNMENT

- 6.1 Complexity of Signaling Networks in Type 2 Diabetes Mellitus
- 6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
- 6.3 First-in-Class Molecular Target Matrix Assessment

7 FIRST-IN-CLASS MOLECULAR TARGET EVALUATION

- 7.1 Pipeline Programs Targeting G Protein Coupled Receptor Kinase 5 (GRK5)
- 7.2 Pipeline Programs Targeting Gastric Inhibitory Polypeptide Receptors (GIPR)
- 7.3 Pipeline Programs Targeting Bone Morphogenetic Protein Receptor Type 1A (BMPR1A), Bone Morphogenetic Protein Receptor Type 1B (BMPR1B) and Bone Morphogenetic Protein Receptor Type 2 (BMPR2)
- 7.4 Pipeline Programs Targeting Solute Carrier Family 13 Member 5 (SLC13A5)
- 7.5 Pipeline Programs Targeting N Formyl Peptide Receptor 3 (FPR3) and N Formyl Peptide Receptor 2 (FPR2)
- 7.6 Pipeline Programs Targeting Neuromedin U receptor 2 (NMUR2) and Neuromedin U receptor 1 (NMUR1)

- 7.7 Pipeline Programs Targeting Peptide YY (PYY)
- 7.8 Pipeline Programs Targeting Apelin Receptor (APLNR)
- 7.9 Pipeline Programs Targeting Insulin Receptor Substrate (IRS1) and Insulin Receptor Substrate (IRS2)
- 7.10 Conclusion

8 STRATEGIC CONSOLIDATIONS

- 8.1 Industry-Wide First-in-Class Deals
- 8.2 Licensing Deals
 - 8.2.1 Deals by Region, Value and Year
 - 8.2.2 Deals by Stage of Development and Value
 - 8.2.3 Deals by Molecule Type and Molecular Target
 - 8.2.4 List of Deals with Disclosed Deal Values
- 8.3 Co-development Deals
 - 8.3.1 Deals by Region, Value and Year
 - 8.3.2 Deals by Stage of Development and Value
 - 8.3.3 Deals by Molecule Type and Molecular Target
 - 8.3.4 List of Deals with Disclosed Deal Values
- 8.4 First-in-Class Programs with and without Prior Licensing or Co-development Deal Involvement

9 APPENDIX

- 9.1 References
- 9.2 Abbreviations
- 9.3 Methodology
 - 9.3.1 Data Integrity
 - 9.3.2 Innovative and Meaningful Analytical Techniques and Frameworks
 - 9.3.3 Evidence Based Analysis and Insight
- 9.4 Secondary Research
 - 9.4.1 Market Analysis
 - 9.4.2 Pipeline Analysis
 - 9.4.3 Licensing and Co-development Deals
- 9.5 Contact Us
- 9.6 Disclaimer

List Of Tables

LIST OF TABLES

Table 1: Type 2 Diabetes Mellitus, Global, Related Indications of T2DM First-in-Class Products, 2018

Table 2: Type 2 Diabetes Mellitus, Global, Key Features of G Protein Coupled Receptor Kinase 5 (GRK5), 2018

Table 3: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting G Protein Coupled Receptor Kinase 5 (GRK5), 2018

Table 4: Type 2 Diabetes Mellitus, Global, Key Features of Gastric Inhibitory Polypeptide Receptor (GIPR), 2018

Table 5: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting Gastric Inhibitory Polypeptide Receptor (GIPR), 2018

Table 6: Type 2 Diabetes Mellitus, Global, Key Features of Bone Morphogenetic Protein Receptor Type 1A (BMPR1A), 2018

Table 7: Type 2 Diabetes Mellitus, Global, Key Features of Bone Morphogenetic Protein Receptor Type 1B (BMPR1B), 2018

Table 8: Type 2 Diabetes Mellitus, Global, Key Features of Bone Morphogenetic Protein Receptor Type 2 (BMPR2), 2018

Table 9: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting Bone Morphogenetic Protein Receptor Type 1A (BMPR1A), Bone Morphogenetic Protein Receptor Type 1B (BMPR1B) and Bone Morphogenetic Protein Receptor Type 2 (BMPR2), 2018

Table 10: Type 2 Diabetes Mellitus, Global, Key Features of Solute Carrier Family 13 Member 5 (SLC13A5), 2018

Table 11: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting Solute Carrier Family 13 Member 5 (SLC13A5), 2018

Table 12: Type 2 Diabetes Mellitus Drugs Market, Global, Pipeline Programs Targeting N-Formyl Peptide Receptor 2 (FPR2) and N-Formyl Peptide Receptor 3 (FPR3), 2018

Table 13: Type 2 Diabetes Mellitus Drugs Market, Global, Pipeline Programs Targeting N-Formyl Peptide Receptor 2 (FPR2) and N-Formyl Peptide Receptor 3 (FPR3), 2018

Table 14: Type 2 Diabetes Mellitus, Global, Key Features of Neuromedin U Receptor 1 (NMUR1), 2018

Table 15: Type 2 Diabetes Mellitus, Global, Key Features of Neuromedin U Receptor 2 (NMUR2), 2018

Table 16: Type 2 Diabetes Mellitus, Global, Global, Pipeline Programs Targeting Neuromedin U Receptor 2 (NMUR2), 2018

Table 17: Type 2 Diabetes Mellitus Drugs Market, Global, Key Features of Targeting

Peptide YY (PYY), 2018

Table 18: Type 2 Diabetes Mellitus Drugs Market, Global, Pipeline Programs Targeting Peptide YY (PYY), 2018

Table 19: Type 2 Diabetes Mellitus, Global, Key Features of Apelin Receptor (APLNR), 2018

Table 20: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting Apelin Receptor (APLNR), 2018

Table 21: Type 2 Diabetes Mellitus, Global, Key Features of Insulin Receptor Substrate 1 (IRS1), 2018

Table 22: Type 2 Diabetes Mellitus, Global, Key Features of Insulin Receptor Substrate 2 (IRS2), 2018

Table 23: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting Insulin Receptor Substrate 1 (IRS1), 2018

Table 24: Type 2 Diabetes Mellitus, Global, Pipeline Programs Targeting Insulin Receptor Substrate 2 (IRS2), 2018

List Of Figures

LIST OF FIGURES

Figure 1: Type 2 Diabetes Mellitus, Global, Innovation Trends in Product Approvals Across the Pharmaceutical Market, 1987-2014

Figure 2: Type 2 Diabetes Mellitus, Global, Post-Marketing-Approval Sales Performance of First-in-Class and Non-First-in-Class Products Across Pharmaceutical Industry (\$m), 2006-2013

Figure 3: Type 2 Diabetes Mellitus, Global, Market by Molecule Type and Molecular Target, 2018

Figure 4: Type 2 Diabetes Mellitus, Global, Pipeline Size by Therapy Area, 2018

Figure 5: Type 2 Diabetes Mellitus, Global, Pipeline by Stage of Development and Molecule Type, 2018

Figure 6: Type 2 Diabetes Mellitus, Global Pipeline by Molecular Target and Stage of Development, 2018

Figure 7: Type 2 Diabetes Mellitus, Global, Pipeline Breakdown of GPCR and Protein Kinase Molecular Target Class, 2018

Figure 8: Type 2 Diabetes Mellitus, Global, Distribution of Pipeline and Marketed Products by Molecular Target Class, 2018

Figure 9: Type 2 Diabetes Mellitus, Global, Distribution of Pipeline Products by First-in-Class Status and Molecular Target Class, 2018

Figure 10: Type 2 Diabetes Mellitus, Global, Percentage Distribution of First-in-Class and Non-First-in-class Pipeline Programs by Stage of Development and Molecular Target Class, 2018

Figure 11: Type 2 Diabetes Mellitus, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target Class, 2018

Figure 12: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 1)

Figure 13: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 2)

Figure 14: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 3)

Figure 15: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 4)

Figure 16: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 5)

Figure 17: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 6)

Figure 18: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 7)

Figure 19: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 8)

Figure 20: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 9)

Figure 21: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 10)

Figure 22: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 11)

Figure 23: Type 2 Diabetes Mellitus, Global, All First-in-Class Pipeline Programs, 2018 (part 12)

Figure 24: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Matrix Assessment for Type 2 Diabetes Mellitus, 2018 (part 1)

Figure 25: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Matrix Assessment for Type 2 Diabetes Mellitus, 2018 (part 2)

Figure 26: Type 2 Diabetes Mellitus, Global, First-in-Class Molecular Target Matrix Assessment for Type 2 Diabetes Mellitus, 2018 (part 2)

Figure 27: Type 2 Diabetes Mellitus, Global, Industry-Wide Licensing Deals by First-in-Class Status and Stage of Development, 2006-2015

Figure 28: Type 2 Diabetes Mellitus, Global, Industry-Wide Licensing Deals by First-in-Class Status, Deal Value, Upfront Payment Value and Stage of Development, 2006-2014

Figure 29: Type 2 Diabetes Mellitus, Global Licensing Deals by Region, Value and Year 2006-2018

Figure 30: Type 2 Diabetes Mellitus, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2018

Figure 31: Type 2 Diabetes Mellitus, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target Class, 2006-2018

Figure 32: Type 2 Diabetes Mellitus, Global, Licensing Deals with Disclosed Deal Values, 2006-2018

Figure 33: Type 2 Diabetes Mellitus, Global, Co-development Deals by Region, Value and Year 2006-2018

Figure 34: Type 2 Diabetes Mellitus, Global, Number and Aggregate Deal Value of Co-development Deals By Stage of Development and Year, 2006-2018

Figure 35: Type 2 Diabetes Mellitus, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2018

Figure 36: Type 2 Diabetes Mellitus, Global, Co-development Deals with Disclosed Deal Values, 2006-2018

Figure 37: Type 2 Diabetes Mellitus, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006-2018 (part 1)

Figure 38: Type 2 Diabetes Mellitus, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006-2018 (part 2)

Figure 39: Type 2 Diabetes Mellitus, Global, First-in-Class Programs with and without Prior Involvement in Licensing or Co-development Deals, 2006-2018 (part 3)

I would like to order

Product name: Frontier Pharma: Type 2 Diabetes Mellitus - Therapies Targeting GPCRs and Protein Kinases Dominate Pipeline, with Strong Repositioning Opportunities into Associated Areas, Including Obesity and Cardiovascular Disease

Product link: <https://marketpublishers.com/r/F3456F708B0EN.html>

Price: US\$ 6,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F3456F708B0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970